No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LAMR240517C125000
- 1.39
- 0.000.00%
15min DelayTrading May 1 15:37 ET
0.00High0.00Low
0.00Open1.39Pre Close0 Volume7 Open Interest125.00Strike Price0.00Turnover50.26%IV6.33%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry1.39Time Value100Contract SizeAmericanOptions Type0.2622Delta0.0358Gamma85.52Leverage Ratio-0.1811Theta0.0069Rho22.42Eff Leverage0.0589Vega
Intraday
- 5D
- 1D
News
Lamar Advertising to Appear at the 52nd Annual J.P. Morgan Global Technology, Media and Communications Conference
Lamar Advertising Company (NASDAQ:LAMR) Q1 2024 Earnings Call Transcript
Lamar Advertising Co (LAMR) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and ...
Decoding Lamar Advertising Co (LAMR): A Strategic SWOT Insight
Earnings Call Summary | Lamar Advertising Co(LAMR.US) Q1 2024 Earnings Conference
The following is a summary of the Lamar Advertising Company (LAMR) Q1 2024 Earnings Call Transcript:Financial Performance:Lamar Advertising reported Q1 revenue growth of 5.3% on an acquisition-adjuste
Research Alert: CFRA Maintains Hold Opinion On Shares Of Lamar Advertising Company
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our target price by $8 to $118
Comments
Upgrades
• $Allegiance(ABTX.US$ : Raymond James Upgrades to Outperform from Market Perform - PT $43
• $Bunge(BG.US$: JPMorgan Upgrades to Overweight from Neutral - PT $106 (from $130)
• $Cerence(CRNC.US$ : RBC Capital Upgrades to Sector Perform from Underperform - PT $27 (from $28)
• $First Mid Bancshares(FMBH.US$ : Raymond James Upgrades to Outperform from Market Perform - PT $45
• $Lamar Advertising Co(LAMR.US$ : Citigroup Up...
• $Allegiance(ABTX.US$ : Raymond James Upgrades to Outperform from Market Perform - PT $43
• $Bunge(BG.US$: JPMorgan Upgrades to Overweight from Neutral - PT $106 (from $130)
• $Cerence(CRNC.US$ : RBC Capital Upgrades to Sector Perform from Underperform - PT $27 (from $28)
• $First Mid Bancshares(FMBH.US$ : Raymond James Upgrades to Outperform from Market Perform - PT $45
• $Lamar Advertising Co(LAMR.US$ : Citigroup Up...
11
Gainers:
• $Cogent Biosciences(COGT.US$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
• $Cogent Biosciences(COGT.US$ +7.9% (announces positive initial clinical data from ongoing phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis)
• $Univar Solutions(UNVR.US$ +7.2% (expands distribution partnership with BASF)
• $Vail Resorts(MTN.US$ +6% (In reaction to earnings/guidance)
• $BeiGene(BGNE.US$ +5.4% (highlights growing portfolio and pipeline targeting hematologic mali...
17
7
Upgrades
• $CME Group(CME.US$ : Atlantic Equities Upgrades to Overweight from Neutral - PT $235
• $Spirit Airlines(SAVE.US$ : JPMorgan Upgrades to Overweight from Neutral - PT $30 (from $24)
• $SciPlay(SCPL.US$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $14.50)
Downgrades
• $Bilibili(BILI.US$ : ICBC Downgrades to Neutral from Outperform - PT $26.20
• $Blueprint Medicines(BPMC.US$ : Citigroup Downgrades to Se...
• $CME Group(CME.US$ : Atlantic Equities Upgrades to Overweight from Neutral - PT $235
• $Spirit Airlines(SAVE.US$ : JPMorgan Upgrades to Overweight from Neutral - PT $30 (from $24)
• $SciPlay(SCPL.US$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $14.50)
Downgrades
• $Bilibili(BILI.US$ : ICBC Downgrades to Neutral from Outperform - PT $26.20
• $Blueprint Medicines(BPMC.US$ : Citigroup Downgrades to Se...
18
Read more